Adagene (FRA:978) Debt-to-Asset : 0.19 (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Adagene Debt-to-Asset?

Adagene's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was €7.88 Mil. Adagene's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was €12.58 Mil. Adagene's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Dec. 2023 was €106.12 Mil. Adagene's debt to asset for the quarter that ended in Dec. 2023 was 0.19.

Adagene Debt-to-Asset Historical Data

The historical data trend for Adagene's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Adagene Debt-to-Asset Chart

Adagene Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Asset

Get a 7-Day Free Trial

0.02

0.10

0.04

0.18

0.19

Adagene Semi-Annual Data
	Dec18	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Debt-to-Asset	Get a 7-Day Free Trial					0.04	0.10	0.18	0.19	0.19

Competitive Comparison of Adagene's Debt-to-Asset

For the Biotechnology subindustry, Adagene's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Adagene's Debt-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Adagene's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Adagene's Debt-to-Asset falls into.

Adagene Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Adagene's Debt-to-Asset for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(7.88	+	12.576)	/	106.123
	=	0.19

Adagene's Debt-to-Asset for the quarter that ended in Dec. 2023 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(7.88	+	12.576)	/	106.123
	=	0.19

Adagene (FRA:978) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Adagene Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Adagene's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Adagene (FRA:978) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Adagene Inc (FRA:978) » Definitions » Debt-to-Asset

Comparable Companies

Traded in Other Exchanges

ADAG:USA

Address

Xinghu Street, Suzhou Industrial Park, 4th Floor, Building C14, No. 218, Jiangsu Province, Suzhou, CHN, 215123

Website

https://www.adagene.com

Adagene Inc platform-driven, clinical-stage biopharmaceutical company engaged in transforming the discovery and development of novel antibody-based cancer immunotherapies. The company's platform is designed to generate therapeutic antibody candidates with functional epitopes and species cross-reactivity as highlighted by the company's immunotherapy pipeline.

Adagene (FRA:978) Headlines

No Headlines